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A b s t r a c t
Background: Digoxin is used in the treatment of atrial fibrillation (AF) and heart failure (HF). It was reported to increase 
the risk of death in HF. Studies on digoxin are based mainly on patients treated some years ago, before the era of common 
b-blocker use. 
Aim: This study aims to show the influence of digoxin in a modern cohort of HF patients on top of the contemporary 
guideline-directed treatment.
Methods: This study retrospectively analyses the Polish part of the European Society of Cardiology Heart Failure Long-Term 
Registry. It includes 912 patients treated for HF between February 2012 and January 2013, and followed until May 2014. At 
baseline, 19.1% took digoxin, 89.6% angiotensin convertase enzyme inhibitors or angiotensin receptor blockers, 91.9% 
b-blockers, and 69.4% mineralocorticoid receptor antagonists. 
Results: Digoxin is associated with increased risk of death after adjustment for significant covariates in patients who have HF 
with reduced ejection fraction (HFrEF) but no AF history (hazard ratio [HR] 2.52, 95% confidence interval [CI] 1.23–5.19; 
p = 0.011), and it does not influence significantly the risk of hospitalisation (adjusted HR 1.46, 95% CI 1.05–1.72; p = 0.11). 
Digoxin use shows no significant association with the risk of death or hospitalisation in patients with AF and HFrEF or HF with 
preserved ejection fraction (HFpEF). Patients on digoxin present a significantly worse clinical status with lower left ventricular 
ejection fraction and higher New York Heart Association class, and fewer of them received the guideline-directed treatment.
Conclusions: Digoxin is associated with increased risk of death in HFrEF patients without AF history receiving the guideline- 
-directed treatment. Digoxin seems to be employed in patients with worse clinical status, which may at least partially explain 
its association with increased risk of death. 
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INTRODUCTION
Digoxin is an old drug used in the treatment of atrial fibrilla-
tion (AF) and heart failure (HF) to slow down heart rate and 
improve symptoms in HF. According to the current European 
Society of Cardiology (ESC) guidelines “it may be considered 
in patients in sinus rhythm with symptomatic HF with reduced 
ejection fraction (HFrEF) to reduce the risk of hospitalisation 
(both all-cause and HF hospitalisations)” [1], which is based on 
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the Digitalis Investigation Group (DIG) study [2]. Moreover, “in 
patients with symptomatic HF and AF, digoxin may be useful 
to slow a rapid ventricular rate, but it is only recommended 
for the treatment of patients with HFrEF and AF with rapid 
ventricular rate when other therapeutic options cannot be 
pursued” [1]. 
The DIG study, the only randomised controlled trial of 
digoxin, was published in 1997, and the ESC guidelines on 
treatment of acute and chronic HF have changed significantly 
since then. We have witnessed growing numbers of patients 
treated with b-blockers, angiotensin converting enzyme in-
hibitors (ACEIs) or angiotensin receptor blockers (ARBs), min-
eralocorticoid receptor antagonists (MRAs), and implantable 
cardioverter-defibrillators (ICDs) or cardiac resynchronisation 
therapy (CRT). During these 20 years, several researchers 
published data that provoked discussion about the safety of 
treatment with digoxin. The most recent studies questioning 
the safety of treatment are those by Vamos et al. [3], Madelaire 
et al. [4], Qureshi et al. [5], Al-Khateeb et al. [6], and Katz 
et al. [7]. Other authors showed no influence of digoxin on 
outcomes of HF patients (e.g. Chamaria et al. [8] and Ziff et 
al. [9]) or confirmed the initial discovery that digoxin de-
creased the risk of hospitalisation in HF patients (e.g. Andrey 
et al. [10], Ahmed et al. [11], and Ziff et al. [9]); some even 
showed improved outcomes of patients on digoxin [11]. 
Although these findings provoked a vivid discussion, 
the patients investigated by the abovementioned research-
ers participated in studies conducted several years ago, and 
therefore included relatively low percentages of patients on 
b-blockers (26%–64%), ACEI or ARB (49%–93%), and MRA 
(10%–29%), with the exceptions of the studies by Al-Khateeb 
et al. [6] and Erath et al. [12]. As stated in the ESC guidelines 
on treatment of acute and chronic HF, “digoxin’s effect on 
top of b-blockers has never been tested” [1]. 
The aim of the study presented herein was to show the 
effect of treatment with digoxin on the risk of mortality and 
hospitalisations in a modern cohort of patients with HF, chosen 
to reflect the current ESC guidelines on usage of digoxin, on 
top of contemporary guideline-directed treatment.
METHODS
ESC Heart Failure Long-Term Registry
The ESC Heart Failure Long-Term Registry was a large pro-
spective study of HF patients. The Polish part of the registry 
included 1126 patients (765 inpatients and 361 outpatients) 
treated for chronic or acute HF between February 2012 and 
March 2013, and followed until May 2014. The mean 
follow-up was 332 days (range 14– 817 days). Evaluation of 
these patients was based on medical history, physical exami-
nation, and laboratory tests taken at baseline visit and after 
12 months. The inpatients were evaluated both on admis-
sion to hospital and on discharge. The primary endpoint was 
death, and the secondary endpoint was HF hospitalisation. 
The registry was approved by the appropriate ethics review 
board at every site that included patients into this registry.
Analysis of digoxin use
This was a retrospective analysis of the Polish part of the ESC 
Heart Failure Long-Term Registry. We included both outpa-
tients and inpatients (of the latter only the data from discharge 
status were taken into account) in our analysis. Complete data 
on survival and rehospitalisations were available for 1030 pa-
tients of the registry; among them, 174 received digoxin at 
baseline and took it throughout the follow-up, and 738 did 
not take digoxin at all; these two groups were included in 
further analyses (912 patients in total). The rest of the patients 
(n = 118) had digoxin employed or discontinued during the 
follow-up, and they were excluded from further analyses to 
rule out the bias from unknown duration of treatment. The 
patients were considered to have HFrEF when the ejection 
fraction was ≤ 45%, and HF with preserved ejection fraction 
(HFpEF) when the ejection fraction was > 45%.
Statistical analysis
Statistical analysis was performed using STATISTICA 12 (Tibco 
Software Inc., Palo Alto, CA, USA). Probability distribu-
tion of continuous variables was tested with Lillefors and 
Shapiro-Wilk tests. The distribution of all the investigated 
variables was found non-normal; hence, the Mann-Whitney U 
test was used. The c2 test was used for categorical variables, 
with Yates’s correction where applicable. Univariate regression 
models, log rank tests, and Kaplan-Maier plots were used to 
assess unadjusted survival. Multivariate analysis of survival was 
performed using Cox proportional hazard regression models 
with adjustment for the parameters that significantly differed 
between the survivors and non-survivors (age, New York 
Heart Association [NYHA] class, AF history, chronic kidney 
disease [CKD], left ventricular ejection fraction [LVEF], B-type 
natriuretic peptide [BNP], blood haemoglobin concentration 
at presentation, ICD/CRT-D therapy, and ACEI/ARB > 50% of 
optimal dose). The data are expressed as mean values with 
standard deviation for continuous variables, and percentages 
for categorical variables. A p value of < 0.05 was considered 
statistically significant for all the tests. 
RESULTS
General characteristics
Overall, 19.1% of patients were treated with digoxin. It is 
worth noting that nearly all the patients took ACEI or ARB 
(91.5% HFrEF and 84.5% HFpEF), b-blockers (95.4% HFrEF 
and 82.8% HFpEF), and MRA (76.0% HFrEF and 52.4% 
HFpEF). There were also 18 patients on ivabradine (2%). 
Baseline statistics are shown in Table 1.
The percentage of patients receiving digoxin increased 
with NYHA class from I to IV (4.6%, 15.1%, 30.5%, and 35.7%, 
respectively; p < 0.001). Patients with HFrEF were more likely 
www.kardiologiapolska.pl
Digoxin in treatment of heart failure
1065
to receive digoxin than those with HFpEF (21.1% vs. 13.3%; 
p = 0.009), and they had a significantly worse clinical status 
with a larger group of patients with NYHA class III/IV com-
pared to HFpEF (32.6% vs. 22.8%; p = 0.005). Prevalence 
of AF in HFpEF patients was higher than in the HFrEF group 
(50.2% vs. 38.3%; p = 0.002), and HFrEF patients with AF 
were more likely to receive digoxin than those with HFpEF 
and AF (35.6% vs. 23.9%; p < 0.001). The non-survivors used 
digoxin more often, were older, had a worse clinical status 
with higher mean NYHA class, more frequent AF history and 
worse kidney function, and less often received the guide-
line-directed treatment compared to the survivors (Table 2). 
There was no difference between the percentages of patients 
on digoxin who died due to cardiac or non-cardiac causes 
(31.5% vs. 33%; p = 0.76). The causes of death are shown 
in Figure 1.
Comparison of patients receiving  
and not receiving digoxin
The patients on digoxin were younger but they presented 
a significantly worse clinical status than those who did not 
receive the drug, they had a lower mean LVEF, a higher death 
rate, and fewer of them received the guideline-directed 
treatment (Table 1). To minimise prescription bias, severe HF 
patients were analysed separately (NYHA III/IV, and HF with 
LVEF < 25%). Those on digoxin were younger, had a higher 
Table 1. Baseline characteristics
General HFrEF (n = 653) HFpEF (n = 233) Total (n = 912)
On digoxin 
(n = 138)
No digoxin 
(n = 515)
p On digoxin 
(n = 31)
No digoxin 
(n = 202)
p On digoxin 
(n = 174)
No digoxin 
(n = 738)
p
Age [years] 61 (14) 64 (13) 0.043 77 (10) 72 (12) 0.018 64 (15) 66 (13) 0.047
NYHA class 2.5 (0.6) 2.2 (0.6) < 0.001 2.5 (0.5) 2.1 (0.6) 0.002 2.5 (0.6) 2.2 (0.6) < 0.001
Non-survivors 33 (24%) 60 (12%) < 0.001 7 (23%) 25 (12%) 0.12 40 (23%) 88 (12%) < 0.001
Hospitalised 72 (52%) 193 (38%) 0.002 7 (23%) 86 (43%) 0.034 82 (47%) 288 (39%) 0.05
Test results
Haemoglobin [mmol/L] 8.4 (1.3) 8.4 (1.2) 0.95 7.9 (1.1) 8.2 (1.2) 0.22 8.3 (1.3) 8.3 (1.2) 0.72
Serum creatinine [µmol/L] 92 (37) 95 (50) 0.94 83 (28) 88 (44) 0.73 90 (35) 93 (49) 0.72
eGFR [mL/min/1.73 m2] 86 (33) 84 (31) 0.70 79 (28) 82 (30) 0.51 85 (32) 84 (32) 0.89
BNP [pg/mL] 1570 (2204) 955 (1166) 0.14 491 (452) 355 (409) 0.09 1276 (1944) 783 (1038) 0.06
NT-proBNP [pg/mL] 5632 (7654) 5248 (6810) 0.94 4001 (3585) 2664 (3482) 0.08 5156 (6986) 4584 (6211) 0.62
LVEF [%] 26 (9) 31 (9) < 0.001 54 (4) 56 (7) 0.08 31 (14) 38 (14) < 0.001
Comorbidities
CKD 27 (20%) 126 (25%) 0.23 7 (23%) 42 (21%) 0.82 34 (20%) 173 (23%) 0.27
AF history 89 (65%) 161 (31%) < 0.001 28 (90%) 89 (44%) < 0.001 119 (68%) 259 (35%) < 0.001
Diabetes mellitus 43 (31%) 165 (32%) 0.86 10 (32%) 61 (30%) 0.82 55 (32%) 233 (32%) 0.89
History of malignancy 7 (5%) 14 (3%) 0.16 1 (0.5%) 10 (5%) 0.97 8 (5%) 24 (3%) 0.39
Device therapy
ICD 44 (31%) 111 (22%) 0 6 (3%) 44 (25%) 120 (16%) < 0.001
PM 5 (4%) 25 (5%) < 0.001 4 (13%) 14 (7%) 0.75 9 (5%) 40 (5%)
CRT-P/CRT-D 26 (19%) 40 (8%) 0 3 (1.5%) 27 (16%) 43 (6%)
Medication
ACEI/ARB 117 (85%) 476 (92%) 0.006 23 (65%) 173 (86%) 0.10 144 (83%) 667 (90%) 0.004
ACEI/ARB > 50% of optimal dose 64 (55%) 327 (69%) 0.005 15 (65%) 130 (75%) 0.30 82 (57%) 468 (70%) 0.002
b-blockers 130 (94%) 493 (96%) 0.45 22 (71%) 171 (85%) 0.06 157 (90%) 682 (92%) 0.34
MRA 117 (85%) 379 (74%) 0.006 23 (74%) 99 (49%) 0.009 145 (83%) 488 (66%) < 0.001
Amiodarone 17 (12%) 76 (15%) 0.46 1 (3%) 11 (5%) 0.93 18 (10%) 87 (12%) 0.68
Data are shown as mean (standard deviation) or number (percentage). ACEI — angiotensin converting enzyme inhibitor; AF — atrial fibrillation; 
ARB — angiotensin receptor blocker; BNP — B-type natriuretic peptide; CKD — chronic kidney disease; CRT-D — cardiac resynchronisation therapy 
with ICD function; CRT-P — cardiac resynchronisation therapy; eGFR — estimated glomerular filtration rate; ICD — implantable cardioverter-
-defibrillator; LVEF — left ventricular ejection fraction; MRA — mineralocorticoid receptor antagonist; NT-proBNP — N-terminal pro–B-type natriuretic 
peptide; NYHA — New York Heart Association; PM — pacemaker
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death rate, lower LVEF, higher incidence of AF, more ICDs and 
CRTs, and were more likely to be treated with MRA (Table 3).
The effect of digoxin on hospitalisations  
and mortality 
Treatment with digoxin was associated with increased risk 
of death (Fig. 2) and hospitalisation in univariate analysis 
(hazard ratio [HR] 1.35; p = 0.017), but the latter disap-
peared after adjustment. HFrEF patients without AF presented 
the highest hazard ratio (Table 4); however, digoxin had no 
significant influence on the risk of death in HFrEF patients 
when patients with mild and severe HF (NYHA III/IV, and 
NYHA I/II, and HF with LVEF < 25%; Table 4) were ana-
lysed separately.
The HFrEF patients with AF history showed no significant 
influence of digoxin on the risk of death or hospitalisation; 
the same was true for the HFpEF patients with or without 
AF history.
DISCUSSION
Key findings
Our study shows new evidence that digoxin is independently 
associated with a higher risk of death in HF patients who 
receive the contemporary guideline-directed treatment, and 
that HFrEF patients without AF history demonstrate the high-
est risk. Furthermore, contrary to other authors, we showed 
that digoxin has no influence on the risk of mortality and 
hospitalisations in HF patients with AF history, regardless 
Table 2. Comparison of survivors and non-survivors (all patients)
General Survivors (n = 784) Non-survivors (n = 128) p
Age [years] 65 (14) 72 (11) < 0.001
NYHA class 2.2 (0.6) 2.5 (0.6) < 0.001
Aetiology 0.052
Ischaemic 408 (52%) 74 (58%)
DCM 265 (34%) 30 (23%)
Other 111 (14%) 24 (19%)
Test results
Haemoglobin [mmol/L] 8.4 (1.2) 7.9 (1.2) < 0.001
Serum creatinine [µmol/L] 90 (45) 109 (54) < 0.001
eGFR [mL/min/1.73 m2] 86 (32) 72 (32) < 0.001
BNP [pg/mL] 682 (740) 1860 (2470) < 0.001
NT-proBNP [pg/mL] 4040 (5617) 8780 (8870) < 0.001
LVEF [%] 37 (14) 34 (16) 0.009
Comorbidities
CKD 148 (18.9%) 59 (46.1%) < 0.001
AF history 311 (39.7%) 67 (52.3%) 0.009
Diabetes mellitus 238 (30.4%) 51 (39.8%) 0.09
History of malignancy 25 (3.2%) 7 (5.5%) 0.19
Device therapy
ICD 140 (17.9%) 24 (18.7%)
PM 37 (4.7%) 12 (9.4%) 0.048
CRT-P/CRT-D 54 (6.9%) 16 (10.9%)
Medication
Digoxin 134 (17%) 40 (23%) < 0.001
ACEI/ARB 707 (90%) 104 (81%) 0.003
ACEI/ARB > 50% of optimal dose 494 (70%) 56 (54%) 0.001
b-blockers 730 (93%) 109 (85%) 0.002
MRA 541 (69%) 92 (72%) 0.51
Amiodarone 85 (11%) 20 (16%) 0.12
Data are shown as mean (standard deviation) or number (percentage). DCM — dilated cardiomyopathy; other abbreviations — see Table 1
www.kardiologiapolska.pl
Digoxin in treatment of heart failure
1067
Figure 1. Causes of death (all patients)
Table 3. Comparison of severe heart failure patients receiving and not receiving digoxin
General NYHA III and IV (n = 273) LVEF < 25% (n = 253)
On digoxin 
(n = 84)
No digoxin  
(n = 189)
p On digoxin 
(n = 81)
No digoxin 
(n = 172)
p
Age [years] 65 (14) 68 (12) 0.037 60 (12) 63 (14) 0.08
NYHA class 3.1 (0.2) 3.1 (0.2) 0.68 2.6 (0.6) 2.4 (0.6) 0.024
Non-survivors 25 (30%) 34 (18%) 0.029 24 (30%) 29 (17%) 0.019
Hospitalised 40 (48%) 77 (41%) 0.29 49 (60%) 77 (45%) 0.019
Test results
Haemoglobin [mmol/L] 8.15 (1.4) 8.05 (1.3) 0.64 8.49 (1.1) 8.40 (1.2) 0.75
Serum creatinine [µmol/L] 95 (42) 107 (75) 0.27 97 (43) 105 (67) 0.24
eGFR [mL/min/1.73 m2] 83 (34) 76 (32) 0.20 85 (36) 78 (30) 0.32
BNP [pg/mL] 1410 (2253) 996 (1349) 0.38 1826 (2477) 1398 (1146) 0.94
NT-proBNP [pg/mL] 5789 (5461) 7623 (8433) 0.49 5761 (7576) 6599 (6579) 0.15
LVEF [%] 29 (14) 34 (15) 0.004 19 (4) 21 (4) 0.07
Comorbidities
CKD 22 (26%) 67 (36%) 0.13 19 (23%) 54 (31%) 0.19
AF history 52 (62%) 67 (36%) < 0.001 44 (54%) 56 (32%) < 0.001
Diabetes mellitus 29 (35%) 71 (38%) 0.73 27 (33%) 59 (34%) 0.77
History of malignancy 4 (5%) 7 (4%) 0.68 3 (4%) 5 (3%) 0.73
Device therapy
ICD 25 (30%) 35 (18%) 33 (41%) 60 (35%)
PM 3 (4%) 11 (6%) 0.002 1 (1%) 9 (5%) 0.033
CRT-P/CRT-D 15 (18%) 19 (10%) 18 (22%) 22 (14%)
Medication
ACEI/ARB 70 (83%) 152 (80%) 0.57 67 (83%) 156 (91%) 0.07
ACEI/ARB > 50% of optimal dose 35 (50%) 92 (61%) 0.14 34 (51%) 93 (60%) 0.22
b-blockers 75 (89%) 173 (92%) 0.55 78 (96%) 166 (97%) 0.93
MRA 67 (80%) 124 (66%) 0.019 70 (86%) 141 (82%) 0.37
Amiodarone 11 (13%) 26 (14%) 0.88 10 (12%) 44 (26%) 0.016
Data are shown as mean (standard deviation) or number (percentage). Abbreviations — see Table 1
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of the type of HF (HFrEF vs. HFpEF) [5, 13–16]. Our study 
confirms the findings of several authors [3–7, 12, 17, 18] who 
showed a negative influence of digoxin on the outcomes of 
HF patients, and contradicts others who showed a neutral 
[9, 19] or a positive effect of digoxin [2, 10, 20–23]. Our 
analysis suggests that worse clinical state of patients treated 
with digoxin might be at least partially responsible for the 
observed association with increased risk of death, which was 
mentioned earlier by only a few authors [24, 25]. 
To our knowledge, this is the first study including patients 
who received the guideline-directed treatment (b-blockers 
91.9%, ACEI or ARB 89.6%, and MRA 69.4%) and who were 
treated with digoxin throughout the follow-up period. This is 
contrary to numerous other studies on digoxin, which ana-
lysed patients treated with digoxin throughout the follow-up 
but without the other modern guideline-directed treatment 
[18, 26], or which included patients treated according to the 
modern ESC guidelines but receiving digoxin only “at some 
point of the follow-up/at baseline” [6, 12], or which did not 
include patients with guideline-directed treatment nor ana-
lysed the length of treatment with digoxin [13–16]. Our study 
also seems to analyse the most up-to-date cohort of patients, 
followed between 2012 and 2014. 
Digoxin in heart failure
Our study has shown that digoxin is independently associ-
ated with a higher risk of all-cause mortality with adjusted HR 
1.87 in a group of 912 HF patients. Two other recent studies 
(both published in 2016) included patients with modern 
treatment, similarly to our study (very high percentages of 
b-blocker-, ACEI/ARB-, and MRA-users). The retrospective 
analysis by Erath et al. [12] of a group of 1020 patients with 
ICD implanted as primary or secondary prevention and with 
or without AF, followed for 10 years, showed adjusted HR of 
1.65; similarly, Al-Khateeb et al. [6] analysed 1075 chronic 
HF patients with or without AF, with LVEF < 45%, chosen 
using propensity score matching, and showed adjusted HR of 
1.74. These two studies showed a harmful effect of treatment 
with digoxin in heterogeneous groups of patients. To rule out 
such a bias in our investigation, we analysed a subgroup of 
patients treated with digoxin according to the current ESC 
guidelines, i.e. with HFrEF and without AF, and we showed 
Figure 2. Survival probability and hospitalisation-free survival probability in heart failure with reduced ejection fraction (HFrEF) 
and heart failure with preserved ejection fraction (HFpEF) (Kaplan-Meier plot; log-rank p); A. Survival probability in HFrEF;  
B. Hospitalisation-free survival probability in HFpEF; C. Survival probability in HFpEF; D. Hospitalisation-free survival probability in HFrEF
A B
C D
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that such patients are especially at risk of death when using 
digoxin (adjusted HR 2.52). 
Contrary to our findings, many authors demonstrated 
a positive impact of digoxin on the risk of mortality and 
hospitalisation. They showed that low serum concentra-
tions of digoxin were associated with improved outcomes 
(0.5–0.7 ng/mL, HR 0.77 [27] or 0.5–0.9 ng/mL, HR 0.77 [20]), 
and that digoxin reduced one-year mortality (HR 0.89) and 
hospitalisation risk (HR 0.82) in HF patients treated with ACEI 
[11]. These authors attributed the increased mortality of pa-
tients on digoxin to its toxicity, i.e. high doses and high serum 
concentrations. Unfortunately, digoxin serum concentrations 
and the exact doses were not available to our analysis. There 
were no differences in the incidence of CKD between the pa-
tients receiving or not receiving digoxin, but the non-survivors 
presented CKD significantly more often. Thus, we cannot rule 
out the influence of overly high digoxin concentrations on the 
outcomes of our patients.
Some authors looked for specific populations benefiting 
from digoxin use, e.g. HF patients with NYHA class III/IV and 
LVEF < 25% [28], while others looked for patients who were 
especially at risk when treated with digoxin, e.g. women with 
hypertension [29]. Digoxin was reported to decrease the risk 
of readmission to hospital [30] and even to improve kidney 
function [21]. However, all this evidence bases mainly on 
the DIG trial and its post hoc analyses. We found only one 
study showing a positive influence of digoxin on mortality 
and morbidity, which was not based on the DIG data [10]. 
All the abovementioned studies were conducted some years 
ago, which makes their conclusions questionable in the era 
of wide use of b-blockers.
Several meta-analyses of the available data were conduct-
ed and gave various results. Chamaria et al. [8] showed that 
digoxin is not associated with increased mortality when used 
for rate control in AF and HF patients. Ziff et al. [9] showed 
a neutral effect of digoxin on mortality and a positive effect on 
hospital readmissions. Two other authors showed an increased 
mortality risk in HF patients (HR 1.14 [3] and HR 1.21 [5]). 
However, these meta-analyses have the same disadvantages as 
the studies they include, i.e. lack of contemporary medication 
and heterogeneous groups of patients (combined HFrEF and 
HFpEF, and both with and without AF).
Our aim was to investigate the use of digoxin in HF 
patients receiving an up-to-date guideline-recommended 
treatment, especially b-blockers, and we showed that di-
goxin is associated with a higher risk of mortality in these 
patients. Two other studies investigated specifically the use 
of digoxin and b-blockers. Fauchier et al. [14] showed that 
digoxin alone has a neutral impact on survival, similarly to the 
lack of rate-control treatment, but the addition of a b-blocker 
significantly improved the outcomes. In their study, treatment 
with b-blocker alone and digoxin plus b-blocker had a similar 
positive effect on the outcomes, but their patients had both HF 
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and AF [14]. Katz et al. [7] reported similar results in a cohort of 
HF patients, some of whom had AF. We show also that fewer 
of the patients on digoxin received the guideline-directed 
treatment, including b-blockers. Our analysis does not allow 
us to ascertain whether this is due to the worse clinical status 
of patients (e.g. patients may not tolerate employment or 
up-titration of HF medication because of low blood pressure 
or bradycardia) or if the worse clinical status is due to worse 
quality of treatment.
Our study confirms the findings of Hashim et al. [23] and 
Ahmed et al. [31] from the Ancillary DIG trial that digoxin does 
not influence the outcomes of patients with HFpEF.
Possible prescription bias
Digoxin is mostly used in patients with severe HF, and it has 
been suggested that digoxin might only be a risk marker [24]. 
Bavendiek et al. [25] argue that the conflicting evidence from 
numerous studies concerning the use of digoxin suggests a pre-
scription bias, which cannot be entirely ruled out by statisti-
cal adjustment for various confounders. Ziff et al. [9] in their 
meta-analysis showed that the studies with the highest HR for 
use of digoxin also present the highest risk of bias. Indeed, our 
analysis shows that the patients on digoxin had a higher mean 
NYHA class and BNP, a lower mean LVEF, and fewer of them 
received the guideline-directed treatment. Moreover, the per-
centage of HF patients receiving digoxin increased with NYHA 
class, which was shown also in other studies [32]. We showed 
that HFrEF patients without AF history present the highest HR; 
however, the harmful effect of digoxin disappears when patients 
with mild and severe HF are analysed separately.
Our study has several strong points. It analyses the most 
up-to-date group of patients, chosen to reflect the current ESC 
guidelines. Our patients were treated with digoxin throughout 
the follow-up to minimise the bias from unknown duration of 
treatment, and nearly all of them received the contemporary 
guideline-directed treatment.
However, we recognise several limitations to our study. 
This was an observational study, which on one hand allowed 
us to see a real-life population of patients, but simultane-
ously did not allow us to rule out hidden bias from unknown 
confounders. Because this was a registry, the data of some 
patients were incomplete. Serum digoxin concentrations and 
the exact doses were not available for analysis. The exact 
length of treatment with digoxin in patients receiving it prior 
to inclusion into the ESC Heart Failure Long-Term Registry 
could not be established.
In conclusion, digoxin is associated with increased risk 
of death in HFrEF patients without AF history receiving the 
guideline-directed treatment. Data suggest that digoxin is 
employed in patients with worse clinical status, which may at 
least partially explain its association with the increased risk of 
death. Digoxin has no significant influence on hospitalisation 
risk in HF patients receiving the guideline-directed treatment.
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